

Date: 14/02/2023

To,
The Board of Directors,
Ishita Drugs & Industries Limited,
Ahmedabad.

LIMITED REVIEW REPORT

We have reviewed the accompanying of unaudited financial results of **ISHITA DRUGS AND INDUSTRIES LIMITED** for the period **01 Oct 2022 to 31 Dec 2022** (The Statement) being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing of Obligation and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim financial information performed by the Independent auditor of the entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with Indian accounting standards prescribe under section 133 of companies Act, 2013 read with relevant rules issued there under and another recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Of Obligation and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For and on behalf of
JAYMIN SHAH & ASSOCIATES
Ahmedabad
M. No. 170863
Chartered Accountants

CA Mayank Sancheti
M No. :170863
Date: 14/02/2023
Place: Ahmedabad
UDIN: 23170863BGRDDK1075

Corp. Office : 410-411, Lilamani Corporate Heights, Opp. Ramapir Brts Bus Stand, Nr. Ozone Aangan, New Wadaj, Ahmedabad - 380013, Gujarat
Branch Office : 504, Palladium Business Hub, Above Pantaloons, Opp. 4D Mall - PVR Cinema, Visat-Gandhinagar Highway, Ahmedabad-382424

☐ CA Mayank Sancheti +91 8000331632 / 7048685472
● GSTIN : 24AAOFJ1119R1ZY

✉ camayanksancheti@gmail.com

ISHITA DRUGS AND INDUSTRIES LIMITED

CIN: L24231GJ1992PLC017054

Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand
Ahmedabad – 382170

Website: www.ishitadrugs.com

Unaudited Financial Results for the Quarter Ended December 31, 2022

Amount in Lacs except Per Share data

Particulars	Quarter Ended			Period Ended		Year Ended
	3 Months Ended	3 Months Ended	3 Months Ended	9 Months Ended	9 Months Ended	12 Months Ended
	Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
	31-Dec-22	30-Sep-22	31-Dec-21	31-Dec-22	31-Dec-21	31-Mar-22
1 INCOME						
Revenue from Operations	325.66	283.55	433.13	944.57	1011.66	1409.05
Other Income	2.33	5.28	1.21	11.25	10.04	10.62
Total Income	327.99	288.83	434.34	955.83	1021.70	1419.67
2 EXPENSES						
(a) Cost of Material Consumed	218.08	217.10	338.97	648.48	738.29	969.21
(b) Purchase of Stock-In-Trade	0.00	9.45	42.10	55.20	50.95	50.95
(c) Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	15.07	(19.88)	(31.13)	(23.65)	(41.79)	(2.97)
(d) Employee Benefit Expense	33.72	29.97	28.53	93.32	82.63	118.08
(e) Finance Cost	0.39	0.16	0.24	0.91	1.94	2.46
(f) Depreciation, Depletion and Amortisation Expense	3.24	3.24	3.65	9.73	10.96	12.98
(g) Other Expense	42.48	33.06	30.49	118.99	121.69	164.66
Total Other Expenses	42.48	33.06	30.49	118.99	121.69	164.66
Total Expenses	312.99	273.11	412.85	902.98	964.68	1315.37
3 Total Profit before Exceptional Items and Tax	15.01	15.72	21.49	52.85	57.02	104.30
4 Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
5 Total Profit before Tax	15.01	15.72	21.49	52.85	57.02	104.30
6 Tax Expense						
7 Current Tax	3.50	4.00	6.00	13.00	14.00	25.00
8 Deferred Tax	0.00	0.00	0.00	0.00	0.00	(1.20)
9 Total Tax Expenses	3.50	4.00	6.00	13.00	14.00	23.80
10 Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00	0.00	0.00	0.00	0.00
11 Net Profit Loss for the period from continuing operations	11.51	11.72	15.49	39.85	43.02	80.50
12 Profit / (Loss) from discontinued operations before tax	0.00	0.00	0.00	0.00	0.00	0.00
13 Tax Expenses of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
14 Net Profit / (Loss) from discontinued operations after tax	0.00	0.00	0.00	0.00	0.00	0.00


Jyeshth Agrawal



15	Share of Profit / (Loss) of associates and joint ventures accounted for using equity method	0.00	0.00	0.00	0.00	0.00	0.00
16	Total Profit / (Loss) for the period	11.51	11.72	15.49	39.85	43.02	80.50
17	Other Comprehensive Income net of Taxes	0.00	0.00	0.00	0.00	0.00	0.00
18	Total Comprehensive Income for the Period	11.51	11.72	15.49	39.85	43.02	80.50
19	Total profit or loss attributable to						
	Profit or loss, attributable to owners of parents	0.00	0.00	0.00	0.00	0.00	0.00
	Total Profit or loss, attributable to non-controlling interests	0.00	0.00	0.00	0.00	0.00	0.00
20	Total comprehensive income for the period attributable to						
	Comprehensive Income for the period attributable to the owners of par	0.00	0.00	0.00	0.00	0.00	0.00
	Total comprehensive income for the period attributable to the owners of parent non-controlling interests	0.00	0.00	0.00	0.00	0.00	0.00
21	Details of Equity Share Capital						
	Paid-Up Equity Share Capital	299.03	299.03	299.03	299.03	299.03	299.03
	Face Value of Equity Share Capital	10.00	10.00	10.00	10.00	10.00	10.00
22	Details of Debt Securities						
	Paid-Up Debt Capital	0.00	0.00	0.00	0.00	0.00	0.00
	Face Value of Debt Securities	0.00	0.00	0.00	0.00	0.00	0.00
23	Reserves Excluding Revaluation Reserves	0.00	0.00	0.00	0.00	0.00	0.00
24	Debenture Redemption Reserve	0.00	0.00	0.00	0.00	0.00	0.00
25	Earnings Per Share						
(i)	Earnings Per Share for continuing operations						
	Basic Earnings / (Loss) per share from continuing operations	0.38	0.39	0.52	1.33	1.44	2.69
	Diluted Earnings / (Loss) per share from continuing operations	0.38	0.39	0.52	1.33	1.44	2.69
(ii)	Earnings Per Share for discontinued operations						
	Basic Earnings / (Loss) per share from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
	Diluted Earnings / (Loss) per share from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
(iii)	Earnings per Equity Share						
	Basic Earnings / (Loss) per share from continuing and discontinued ope	0.38	0.39	0.52	1.33	1.44	2.69
	Diluted Earnings / (Loss) per share from continuing and discontinued op	0.38	0.39	0.52	1.33	1.44	2.69
26	Debt Equity Ratio*	0.00	0.00	0.00	0.00	0.00	0.00
27	Debt Service Coverage Ratio*	0.00	0.00	0.00	0.00	0.00	0.00
28	Interest Service Coverage Ratio*	0.00	0.00	0.00	0.00	0.00	0.00


* The Company has no long term debt as on date

Jaydin Agrawal



NOTES

1. The above Financial Results were reviewed by the Audit Committee and thereafter were approved and taken on record by the Board of Directors in their meeting held on February 14, 2023.
2. The Limited Review of the results has been completed by the Statutory Auditors of the Company.
3. As per Indian Accounting Standard (IndAS) "Operating Segment", the Company's business falls within a single business segment viz. "Pharmaceutical Business".
4. The financial results for the quarter ended 31st December, 2022 are Ind AS compliant. The management has exercised necessary due diligence to ensure that the financial results give a true and fair view. This information has not been subjected to limited review or audit.
5. Previous quarter's amounts have been re-grouped/re-classified, wherever considered necessary to make them comparable with those of the current quarter.
6. Results are available at Company's website www.ishitadrugs.com and also at www.bseindia.com.

For, **ISHITA DRUGS AND INDUSTRIES LIMITED****JAGDISH AGRAWAL****MANAGING DIRECTOR****DIN: 01031687**Place **Ahmedabad**Date **14-Feb-2023**